Loading clinical trials...

Health Education Approach to Lung Screening | Clinical Trials | Clareo Health

RECRUITINGNA

Health Education Approach to Lung Screening

Health Education Approach to Lung Screening (HEALS)

NCT06070870•Virginia Commonwealth University

Summary

Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)

Detailed Description

This is a single-arm study of a patient navigation intervention to increase access to lung cancer screening (LCS).

Eligibility

Age

50 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Meets current USPSTF guidelines for lung cancer screening (LCS)
•20 pack-year smoking history Note: A pack-year is a way of calculating how much a person has smoked in their lifetime.
•One pack-year is the equivalent of smoking an average of 20 cigarettes-1 pack-per day for a year.
•Currently smokes or has quit smoking within the past 15 years
•Identifies as Black or African-American Note: Both Hispanic/Latino and Non-Hispanic/Latino patients are eligible as long as they also identify as Black or African-American (eg, Afro-Latino).
•Willing to complete all navigation-related study activities
•Able to understand and the willingness to sign a written informed consent document

Exclusion Criteria

•Known history of cancer (except squamous cell skin cancer), or coughing up blood in the past 5 years, as reported by the individual
•Has undergone a previous lung cancer screening
•Inability to speak English
•Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Locations (3)

University of North Carolina-Chapel Hill

Carrboro, North Carolina, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Virginia Commonwealth University

Richmond, Virginia, United States

Key Dates

Start Date

October 10, 2023

Primary Completion Date

March 31, 2027

Completion Date

April 30, 2027

Last Updated

March 16, 2026

Enrollment

675

ESTIMATED participants

Conditions

Lung Cancer

Interventions

Patient Navigation

BEHAVIORAL

Contacts

Massey IIT Research Operations

CONTACT

804-628-6430 masseyepd@vcu.edu

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITINGPHASE3

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Health Education Approach to Lung Screening

Inclusion Criteria

Exclusion Criteria

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)